Ten-Year Epidemiology and Antimicrobial Susceptibility of Pediatric Staphylococcal Scalded Skin Syndrome: A Retrospective Study From a Tertiary Referral Center
Listen to this summary
This study aimed to investigate the long-term epidemiology and antimicrobial susceptibility patterns of pediatric Staphylococcal scalded skin syndrome (SSSS) over a decade at a tertiary referral center. The authors found that methicillin-susceptible Staphylococcus aureus was the predominant pathogen, with high susceptibility to first-line β-lactam antibiotics and favorable clinical outcomes, providing a valuable baseline for future antimicrobial resistance monitoring.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Pediatric dermatology
View all →Jun 1, 2026 · Pediatric dermatology
Unilateral Forearm Ulceration in a Newborn: Thinking Outside the Box (Compartment)
May 31, 2026 · Pediatric dermatology
Safety of Dupilumab and Risk of Cutaneous T-Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data-Driven Guide to Counseling Patients and Families
More in Dermatology
View all →Nov 19, 2026 · Lancet (London, England)
Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.
Nov 19, 2026 · Lancet (London, England)
Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).
Nov 19, 2026 · Lancet (London, England)
Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.
Nov 19, 2026 · The New England journal of medicine
Assessing Multiple Treatment Regimens for Tuberculosis.
Nov 18, 2026 · The New England journal of medicine
Acute Respiratory Distress Syndrome.
Nov 17, 2026 · Lancet (London, England)
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


